Cell MedX (Cell MedX) Debt-to-Equity : -0.45 (As of Feb. 2024)

View and export this data going back to 2013. Start your Free Trial

What is Cell MedX Debt-to-Equity?

Cell MedX's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Feb. 2024 was $0.32 Mil. Cell MedX's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Feb. 2024 was $0.00 Mil. Cell MedX's Total Stockholders Equity for the quarter that ended in Feb. 2024 was $-0.71 Mil. Cell MedX's debt to equity for the quarter that ended in Feb. 2024 was -0.45.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Cell MedX's Debt-to-Equity or its related term are showing as below:

CMXC' s Debt-to-Equity Range Over the Past 10 Years
Min: -0.68 Med: -0.36 Max: -0.11
Current: -0.45

During the past 12 years, the highest Debt-to-Equity Ratio of Cell MedX was -0.11. The lowest was -0.68. And the median was -0.36.

CMXC's Debt-to-Equity is not ranked
in the Medical Devices & Instruments industry.
Industry Median: 0.21 vs CMXC: -0.45

Cell MedX Debt-to-Equity Historical Data

The historical data trend for Cell MedX's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cell MedX Debt-to-Equity Chart

Cell MedX Annual Data

Trend

May14

May15

May16

May17

May18

May19

May20

May21

May22

May23

Debt-to-Equity

Get a 7-Day Free Trial

-0.29

-0.33

-0.19

-0.31

-0.42

Cell MedX Quarterly Data
	May19	Aug19	Nov19	Feb20	May20	Aug20	Nov20	Feb21	May21	Aug21	Nov21	Feb22	May22	Aug22	Nov22	Feb23	May23	Aug23	Nov23	Feb24
Debt-to-Equity	Get a 7-Day Free Trial															-0.38	-0.42	-0.41	-0.41	-0.45

Competitive Comparison of Cell MedX's Debt-to-Equity

For the Medical Devices subindustry, Cell MedX's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cell MedX's Debt-to-Equity Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Cell MedX's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Cell MedX's Debt-to-Equity falls into.

Cell MedX Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Cell MedX's Debt to Equity Ratio for the fiscal year that ended in May. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(1.001	+	0)	/	-2.385
	=	-0.42

Cell MedX's Debt to Equity Ratio for the quarter that ended in Feb. 2024 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.322	+	0)	/	-0.71
	=	-0.45

Cell MedX (OTCPK:CMXC) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Cell MedX Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Cell MedX's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Cell MedX (Cell MedX) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Cell MedX Corp (OTCPK:CMXC) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

123 W. Nye Lane, Suite 446, Carson City, NV, USA, 89706

Website

https://www.cellmedx.com

Cell MedX Corp is an early stage development company focused on the discovery, development and, commercialization of therapeutic products for patients with diseases such as diabetes, by developing technologies to help manage the illness and related complications. The company's product portfolio consists of electromedical technologies, ebalance, and others.

Executives

Richard Jeffs	10 percent owner	FLAT 7, 6 ENNISMORE GARDENS, LONDON X0 SW7 1NL
Dwayne Yaretz	director, officer: Chief Executive Officer	SUITE 1050 WEST PENDER STREET SUITE 2250, VANCOUVER A1 V6E 3S7
Bradley S Hargreaves	10 percent owner	904-1616 BAYSHORE DR, VANCOUVER A1 V6G3L1
Frank Mcenulty	director, officer: CEO, CFO, Treas., Sec	4182 N. VIKING WAY, SUITE 216, LONG BEACH CA 90808-1475
Joao Dacosta	director, officer: COO	#810 - 789 WEST PENDER STREET, VANCOUVER A1 V6C 1H2
George Adams	director	7535 CONSERVATION ROAD, GUELPH A6 N1H6J1
Terrance George Owen	director, officer: CEO	635 FOURTH LINE (UNIT 1), OAKVILLE A6 L6L 5BO
John David Sanderson	officer: Chief Medical Officer	9 ISLANDVIEW, IRVINE CA 92604
Yanika S Silina	officer: CFO, Treasurer and Secretary	789 WEST PENDER STREET, UNIT 810, VANCOUVER A1 V6C 1H2
Jean M Arnett	10 percent owner	121 - 3989 HENNING DRIVE, BURNABY A1 V5C 6P8
Ean Kremer	director, officer: Chief Technology Officer	C/O PLANDEL RESOURCES, INC., 4575 DEAN MARTIN DRIVE, STE. 2206, LAS VEGAS NV 89103

Cell MedX (Cell MedX) Headlines

From GuruFocus

Cell MedX Insider Buys 22,500 Shares

By Kyle Ferguson Kyle Ferguson • 11-11-2016